During the last several years, research has produced a significant amount of knowledge concerning the characteristics of human cd T lymphocytes. Findings regarding the immune functions of these cells, particularly their natural killer cell-like lytic activity against tumor cells, have raised expectations for the therapeutic applications of these cells for cancer. Pharmaceutical companies have produced selective agonists for these lymphocytes, and several teams have launched clinical trials of cd T cell-based cancer therapies. The findings from these studies include hematological malignancies (follicular lymphoma, multiple myeloma, acute and chronic myeloid leukemia), as well as solid tumors (renal cell, breast and prostate carcinomas), consisting of samples from more than 250 patients from Europe, Japan and the United States. The results of these pioneering studies are now available, and this short review summarizes the lessons learned and the role of cd T cell-based strategies in the current landscape of cancer immunotherapies.
INTRODUCTION
Since the discovery of cd T cells in the late 1980s, a significant amount of knowledge has accumulated regarding human cd T lymphocytes. The unconventional immune functions of these cells, and notably, their histocompatibility leukocyte antigen-unrestricted cytotoxic activity against malignant cells have raised expectations for their use in therapeutic applications for cancer. In addition, because various selective agonists for human cd T lymphocytes have been synthesized, several clinical trials involving cd T cell-based therapies in cancer patients have been launched around the world. The investigations included patients with follicular lymphoma, multiple myeloma and acute myeloid leukemia, as well as nonhematological malignancies, such as renal cells, breast and prostate carcinomas, totaling nearly 250 patients in Europe, Japan and the United States. By 2012, results have been available from most of these pioneering studies, and some conclusions can now be drawn. This review summarizes these studies and considers their results in the greater landscape of current cancer immunotherapies.
RATIONALE FOR HARNESSING cd CELLS IN CANCER IMMUNOTHERAPY
Human cd T lymphocytes comprise several subsets of cells defined by their T-cell receptor (TCR), the most prominent of which in circulating blood is composed of cells expressing the V gamma 9 V delta 2 TCR (hereafter referred to as Vcd9Vcd2 cd T cells). This subset of lymphocytes is not present in mice, restraining preclinical studies either to xenografts in immunodeficient mice or nonhuman primate models. The primary reasons for involving cd cell activation in cancer therapies will be summarized below only briefly, as this topic has recently been reviewed. [1] [2] [3] [4] First, the hallmark characteristic of T lymphocytes expected to interact with cancer cells is their capacity to infiltrate tumors. Accordingly, tumor-infiltrating gamma delta T lymphocytes (cd TILs) were detected in a broad spectrum of malignancies. [5] [6] [7] cd TILs, primarily of the Vc9Vd2 cd T cell type, were reported in renal cell carcinomas, albeit with controversial prognostic values. [7] [8] [9] [10] Nasopharyngeal carcinoma patients carry Vc9Vd2 cd T lymphocytes that are functionally impaired in blood 11 but are able to infiltrate and reduce xenografted nasopharyngeal tumors in mice. 12 Likewise, orthotopic xenografts of breast tumors 13 or bladder carcinomas 14 in mice infused with human TCRVc9Vd2 1 lymphocytes also show strong tumor infiltration by cd TILs and subsequent arrest of tumor growth. In a B-cell depletion assay from cynomolgus monkeys treated with a phosphoantigen plus interleukin-2 (IL-2) and rituximab, endogenous cytotoxic cd T cells were enriched in lymph nodes in which CD20 1 B cells had been depleted. 15 Radiolabeling and imaging experiments (our unpublished results) have confirmed the observed cd cell accumulation at tumor sites, illustrating the capacity of these cells to infiltrate tumor sites in vivo. Additionally, when autologous transplants of In 111 -radiolabeled Vc9Vd2 T cells were tracked in 18 patients with advanced solid tumors, the radiolabeled cells trafficked predominantly to the lungs, liver and spleen, as well as to metastatic tumor sites outside of these organs in some patients. 16 In breast, ovarian, prostate and colorectal cancers, cd TILs also included cells that were negative for the Vc9Vd2 TCR. [5] [6] [7] Vd1 1 cd TILs are present in melanoma, and the infiltration of these cells into necrotizing melanoma correlates with survival. 17 Orthotopic xenografts of the HT29 colon cancer cells in mice infused with human TCRVd2 2 cd T lymphocytes also carried cd TILs that impaired tumor development. 18 In prostate and breast tumors, however, Vd1 1 cd TILs are rather immunosuppressive for dendritic cells and T cells 19 and favor the growth of the tumor through IL-10 release. 20 The second hallmark of T lymphocytes expected to attack tumors is their histocompatibility leukocyte antigen-unrestricted cytotoxic capacity for cancer cells, as well as their ability to secrete adequate cytokines. In vitro, TCRVc9Vd2 1 lymphocytes exert a potent cytotoxic activity against a broad spectrum of malignancies. Activated cd T lymphocytes can kill Burkitt's and non-Hodgkin lymphoma (NHL) of both B-cell and T-cell types, such as follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, B-cell chronic lymphocytic leukemia, anaplastic large-cell lymphoma and acute lymphocytic leukemia. 21 These cells also kill acute myeloid leukemia cells, 22 chronic myeloid leukemia cells 23 and multiple myeloma cells. 24, 25 Activated cd T lymphocytes are also capable of killing a broad spectrum of solid malignancies, while sparing normal tissues. For example, although activated cd T lymphocytes from patients with glioblastoma multiforme appear anergized, these cells can kill corresponding target cells in vitro. 26, 27 Furthermore, these cells are also capable of killing metastatic renal cell carcinomas, mammary carcinomas, prostate carcinomas and colorectal carcinomas, again while sparing the normal, untransformed cells (reviewed in Ref. 28 ). The various pathways and cytokines involved in these cytolytic activities have been reviewed elsewhere 29 and will not be discussed here. 50 of 0.01/mM). 30 The in vitro and in vivo proliferation of TCRVc9Vd2 1 T cells activated by phosphoantigens or aminobisphosphonates requires an exogenous supply of IL-2.
RESULTS FROM CANCER CLINICAL TRIALS BASED ON ACTIVATED cd T LYMPHOCYTES Our current knowledge of the in vivo bioactivity of human cd T cells in cancer essentially relies upon in vivo activation of patients with phosphoantigens/IL-2 or aminobisphosphonates/IL-2 and on the adoptive transfer of autologous cd T lymphocytes preactivated ex vivo with the aforementioned molecules.
NHL of the B-cell type is highly sensitive to cd T cell-mediated lytic activity; therefore, a preliminary pilot study by Wilhelm's team examined toxicity, in vivo activation of cd T cells and antilymphoma efficacy of pamidronate/IL-2 in 19 patients with relapsed/refractory low-grade NHL or multiple myeloma. 32 The first group (10 patients) received pamidronate (90 mg/3 h intravenous (i.v.) on day 1), followed by IL-2 (from day 3 to day 8 by continuous 24-h i.v. infusions of increasing dosages from 0.25 to 3 million IU/m 2 ). Neither cd T-cell activation nor response to treatment was determined in this group. Therefore, a second group consisting of nine patients was preselected for an analysis of the in vitro cd T-cell response to pamidronate/IL-2. These patients received pamidronate (as above), followed by increasing dosages of IL-2 (0.25-2 million IU/m 2 , 6-h i.v. bolus infusions from day 1 to 6). In this group, significant in vivo responses by cd T cells were observed (five patients, 55% of total), with three patients achieving objective responses (33%, partial response). The authors thus demonstrated that pamidronate administered with low-dose IL-2 is well tolerated and induces a specific cd cell amplification; furthermore, the authors found that the clinical response to this treatment observed in the patients, i.e., stabilization or partial response, is linked to cd T-cell proliferation in vivo. These clinical data were the first to demonstrate the therapeutic potential of cd cells in patients with B-cell cancers.
Following the aforementioned trial from Germany, a second study was launched in Palermo by Dieli's group. This team administered zoledronate (4 mg i.v., 15-min infusion every 3 weeks for 3 months) to nine cancer patients with bone metastases (three females with breast cancer, six males with prostate cancer) to determine if the bisphosphonate alone affected maturation of circulating effector Vc9Vd2 cells. 33 The results of this study showed that zoledronate induced the in vivo development of Vc9Vd2 cells into the interferon-c (IFNc)-producing effector subset, which is known to provide stronger antitumor responses in preclinical studies.
As indicated by its partial responses to treatment with recombinant IL-2 or IFN-a, metastatic renal cell carcinoma is resistant to conventional treatments but is quite immunogenic and sensitive to the immune system. Therefore, a pilot study on the effects of zoledronate and IL-2 was conducted in the United States by Malkovsky's group in 12 patients with metastatic renal cell carcinoma. 34 This trial sought to determine whether activation of the patients' TCRVc9Vd2 1 lymphocytes improved clinical outcomes. For six patients, the regimen consisted of three successive weekly cycles of intravenous injections of zoledronate (4 mg, day 1) with IL-2 (7 million IU/m 2 /day, from day 1 to day 5). For three patients, the regimen consisted of four successive weekly cycles of i.v. injections of zoledronate (4 mg, day 1) with subcutaneous (s.c.) administration of IL-2 (1 million U/m 2 /day, from day 1 to day 5). For three patients, this regimen was amended to include dose escalation of zoledronate. All patients also took a supplement of oral calcium and vitamin D during the regimen and had received premedication with oral acetaminophen. Adverse events, primarily of grade 1-2, which are typical of IL-2 monotherapy, were recorded in all patients, but no partial or complete responses were observed. Furthermore, the treatment induced a marked decrease in the in vitro TCRVc9Vd2 1 T-cell response for the majority of the patients, with only one patient demonstrating in vivo proliferation of the targeted cd lymphocytes 8 days after the first cycle.
Because prostate cancer patients harbor zoledronate-responsive cd cells, 35 a phase I clinical trial in 18 patients with metastatic hormonerefractory prostate cancer was performed by Dieli's group. 36 Subjects were randomized into two groups, which received either zoledronate alone (group A: 4 mg i.v. every 21 days) or zoledronate with IL-2 (group B: identical dose of zoledronate, plus 0.6 million IU IL-2 s.c. immediately after zoledronate). All patients also received calcium supplements and vitamin D daily, and the treatment was performed for 1 year. Toxicity in the patients was moderate, including a transient flu-like syndrome 3 days after the first administration of zoledronate/ IL-2 (67% of subjects) or zoledronate alone (22%), as reported earlier for multiple myeloma and NHL patients. 32 A significant clinical response, including higher survival, was observed in group B during the 1-year follow-up. In addition, this outcome correlated with greater numbers of blood cd T cells and with increased rates of effector memory TCRVc9Vd2 1 T cells (i.e., cd cells producing IFN-c, perforin and TNF-related apoptosis-inducing ligand (TRAIL)). Using an identical treatment regimen as the zoledronate/IL-2 combination trial, a phase I trial was conducted by the same group in 10 therapeutically terminal, advanced metastatic breast cancer patients. With results from three cd cell-responsive patients reaching either disease stabilization (two patients) or partial remission (one patient), the authors could correlate the clinical outcomes to blood cd T-cell numbers. 37 In France, using the synthetic phosphoantigen BrHPP (IPH1101), Bennouna and colleagues 38 conducted a phase I trial in 28 patients with solid tumors to determine the maximum-tolerated dose and safety of this drug when combined with low doses of IL-2. Patients received BrHPP alone (1 h i.v. infusions with increasing dosages from 200 to 1800 mg/m 2 ) during cycle 1 and then received BrHPP in combination with IL-2 (1 million IU/m 2 , s.c. from day 1 to day 7) during subsequent cycles (day 1, every 3 weeks). Pharmacodynamic data from the resulting 109 treatment cycles demonstrated that BrHPP induces in vivo cd T-cell amplifications, for which the magnitudes depend upon the dose of phosphoantigen and presence of IL-2. The treatment was generally well tolerated at most doses, causing little dose-limiting toxicity, except for the appearance of cytokine release syndrome following the first infusion of the highest dose (1800 mg/m 2 ) in two patients. Given these findings, the conditions for safe and efficient use of BrHPP/IL-2 in patients have now been determined. Given BrHPP's safety profile, its in vivo bioactivity and its use in a preclinical study with BrHPP/IL-2 and rituximab in NHL patients, 15 a multicentric phase II study using the drug was launched by Innate Pharma in relapsed follicular lymphoma patients. This study involved 45 follicular lymphoma patients who had previously received (up to four) previous lines of therapy using rituximab, at least once. The primary objective was to assess the efficacy of BrHPP compared to that of rituximab alone, which is 40% of overall responses (Davis, JCO, 2000) . The secondary objective was to establish the pharmacodynamics (PD) of BrHPP in these patients. Patients received rituximab (375 mg/m 2 , 4 times, weekly) on days 0, 7, 14 and 21, BrHPP (750 mg/m 2 , 3 times, every 3 weeks) plus IL-2 (8 M IU daily for 5 days, every 3 weeks) on days 8, 29 and 50, and IL2 alone (identical dose) on days 11, 12, 13 and 14 after each BrHPP/IL-2 injection. Side effects were easily managed in most patients. The treatment induced strong and specific amplification of TCRVc9Vd2 1 T lymphocytes in 39 of the 45 patients, although this response peaked 1 week after the first injection of BrHPP and further declined upon subsequent injections. However, these cells showed phenotypic and functional maturation into Th1 and cytotoxic effector memory cells expressing FccRIIIa (CD16). Accordingly, the release of Th1 cytokines (IFN-c, tumor necrosis factor-a), as well as rituximab-mediated antibody-dependent cell cytotoxicity (ADCC) activity, was maximal after the second and third injections of BrHPP. In parallel, natural killer cell numbers were slightly increased by the treatment, whereas no other IL2-responsive subset, including regulatory T cells (Tregs), was quantitatively affected. In addition to these pharmacodynamics, the overall clinical results could be drawn from 38 evaluable patients. This group consisted of 10 patients (26% of total) with complete response (CR) and led to 17 overall response rate (ORR) (45%). In addition, the therapeutic efficacy correlated with biological markers, with the greatest benefits being observed in patients with low follicular lymphoma international progression index (FLIPI) (Figure 1) . Therefore, the combination of BrHPP and rituximab in immunotargeted therapy produces very encouraging results, particularly for follicular lymphoma patients with unfavorable FccRIIIa gene polymorphisms (F/F or V/F, 95% of the patients), with very manageable side effects overall. Although such promising results would require large-scale, randomized clinical trials to validate this exciting new concept, these studies demonstrate the enormous anticancer potential of cd cell-based therapies in combination with therapeutic antibodies. Cancer immunotherapy trials with autologous cd T cells have been investigated in parallel by Japanese, Australian and French groups. The French company Innate Pharma has conducted a phase I study in 10 patients with metastatic renal cell carcinoma 39 to determine the maximum-tolerated dose of autologous TCRVc9Vd2 1 cd T cells and the safety of these cells as a therapeutic product. Patients received a 1-h i.v. infusion of their own TCRVc9Vd2 1 cd T lymphocytes during treatment cycle 1, after which the patients were given the lymphocytes in combination with a low dose of IL-2 (s.c., 2 million IU/m 2 from day 1 to day 7) in the two subsequent cycles at 3-week intervals. The dose of TCRVc9Vd2 1 cd T cells was increased from 1310 9 cells to as high as 8310 9 cells. Immunomonitoring demonstrated that the injected cells were initially cleared from the blood and reappeared at the conclusion of the IL-2 administration. Dose-limiting toxicity (characterized by disseminated intravascular coagulation) occurred in one patient at a dosage of 8310 9 cells; other adverse events included gastrointestinal disorders, flu-like symptoms, and hypotension with tachycardia, resulting from the co-administration of lymphocytes and IL-2. These results suggest that this cell-based therapy is well tolerated and therapeutically interesting, as six patients showed stabilized disease following this treatment.
In parallel with these studies, Kobayashi's group at Tokyo Women's Hospital investigated seven patients with advanced renal cell carcinoma engrafted with autologous cd T cells. 40 Patients received from 1 to Lessons from cd T cell-based cancer immunotherapy trials JJ Fournié et al 37 400 million of their autologous cd cells preactivated using phosphoantigens (by i.v. infusion every week, 6-12 times with IL-2 at 0.7 million IU/patient, with i.v. infusion conducted over 2 h). All patients had IL-2 related non-severe adverse events during the therapy, indicating that the treatment was quite well tolerated, and four out of the seven patients showed a significant in vivo cd T-cell expansion and production of IFN-c in response to phosphoantigen in vitro. The clinical benefit was moderate, however, as only three out of the seven patients (42%) presented slower tumor growth and all of the patients died.
More recently, however, the same team reported a far better outcome for a patient with lung metastasis following a radical nephrectomy for a renal cell carcinoma that was unresponsive to IFN-a. This patient received the following treatment: zoledronate (4 mg i.v. over 30 min) simultaneously with IL-2 (1.4 million IU i.v. over 2 h) and phosphoantigen-preactivated autologous cd cells (from 0.3310 9 to 3.5310 9 cells, i.v.) on day 0, followed daily by an identical dose of IL-2 over days 1-4. This monthly cycle was repeated over a period of 6 months. Although no serious adverse events occurred, this immunotherapy yielded much greater cd T-cell counts and IFN-c production in vivo, along with complete remission of the patient, which is currently ongoing 2 years following the study without treatment. Therefore, the authors concluded that cd cell-based immunotherapy is a clinically beneficial and safe therapeutic option for patients with advanced renal cell carcinoma, whose rates of circulating cd cells might constitute a favorable prognostic indicator. 41 In parallel, Medinet and the Seta Clinic Group in Tokyo also validated the technical feasibility of large-scale, zoledronate-based cd Tcell expansion for cell-based therapy. These groups examined the effects of i.v. injection of 2310 9 -4310 9 cells/patient in six healthy volunteers, 10 patients with advanced non-small cell lung cancers, five patients with bone metastases from prostate or breast cancer, four patients with lung metastases from colon cancer 42 and six multiple myeloma patients. 43 This team further enrolled 25 additional patients carrying various solid tumors who had not undergone treatment with statins (blockers of endogenous phosphoantigen biosynthesis) for zoledronate-activated TCRVc9Vd2 1 cd T cell-based immunotherapy. Two of these patients received cd cells 3 times, five patients 4 times, one patient 5 times and 17 patients 6 times. Overall, cd cells from only three individuals were insufficiently amplified (,10 8 cells) by the process, whereas cells from all of the other patients expanded efficiently enough for the reinfusion. The authors also reported that patients who had been pre-treated with cells or concurrently treated with cells and either zoledronate or chemotherapy (or both) generally had suppressed cd cell proliferation. Although the tumor response could not be assessed in all patients, six out of the 25 enrolled showed disease stabilization. 44 Non-small cell lung cancer cells are also recognized and killed by human TCRVc9Vd2 1 cd T cell; therefore, 10 non-small cell lung cancer patients were enrolled to receive autologous cd T-cell immunotherapy 3-12 times, every 2 weeks. One serious adverse event (grade 3 pneumonia) was recorded, and neither a complete response nor stabilization was observed. However, the 'functional assessment of cancer therapy-biologic response modifier scores' of all but one patient were either stable or improved during immunotherapy. Furthermore, six patients were alive at the end of the observation (240-850 days), demonstrating the potential of cd cell therapy for this condition. 45 Likewise, Nicol's team in Brisbane, Australia recently reported that when autologous transplants of In 111 -radiolabelled TCRVc9Vd2 1 cd T cells were tracked in 18 patients with advanced stages of various solid tumors, the cells trafficked predominantly to the lungs, liver and spleen in all patients but also to metastatic tumor sites in some patients. No dose-limiting toxicity was reported in this study, and three out of the 18 patients had clinical responses while continuing their previously ineffective chemotherapy. These observations led the authors to conclude that zoledronate-activated TCRVc9Vd2 1 cd T cells offer clinical benefits when administered in combination with other drugs. 16 
LESSON I: ADVANCES IN cd T-CELL CANCER IMMUNOTHERAPIES

Safety of cd T-cell activation in patients
The aforementioned pioneering trials have defined conditions for the safe use of phosphoantigens and zoledronate for the activation of cd T cells in patients. Flu-like symptoms, but no cd cell expansion, are generally induced with low doses of stimuli (e.g., 200-1800 mg/m 2 BrHPP) without IL-2, while higher doses of stimuli co-injected with IL-2 increase the level of cd cell expansion and concomitantly increase the frequency of drug-related toxicity and severity of adverse events. The grade 3 and 4 severity of adverse events that has recurrently been reported is characterized by thrombophlebitis, thrombosis, hyperglycemia, hypocalcemia, chest and musculoskeletal pain, gastritis, myocardial infarction and renal creatinine toxicity. When these drugs are administered concurrently with IL-2, the maximum tolerable doses for BrHPP and zoledronate are 1500 and 4 mg/m 2 (every 28 days), respectively. The latter treatment induces febrile symptoms comparable to those induced by BrHPP, but these symptoms are accompanied by calcium release toxicity and osteonecrosis of the jaw in rare cases.
The pharmacodynamics of phosphoantigens administered to humans has been established When injected i.v. into non-human primates, BrHPP can activate circulating cd cells, despite its extremely short half-life (only a few minutes long). 46 The half-life of zoledronate, in contrast, is far longer (146 h). Whichever stimulus is utilized to induce cd T cells, the kinetics of the ensuing proliferation of cd T cells in human blood typically peaks between days 6 and 8, and the amplitude of the proliferative response directly relates to the presence of IL-2 and the dose of BrHPP or bisphosphonate. Most specifically in regard to these lymphocytes, the antigen-driven activation of these cells leads to progressively decreased responses to subsequent stimulations, or tachyphylaxis.
38,46
Dependence on IL-2 for cd cell activation in vivo The use of IL-2 in cancer immunotherapy has been widely debated, owing to this cytokine's intrinsic toxicity. In spite of this toxicity, several conditions can be treated with low-dose IL-2-based regimens, such as renal and prostate carcinomas. Therefore, the aforementioned protocols have carefully determined the optimal doses and formulations for the use of this cytokine in therapies harnessing cd T cells, resulting in limited IL-2-related adverse events. In these trials, IL-2 also elevated the frequency of Tregs, which can inhibit cd T-cell responses or even induce regulatory cd T cells, according to in vitro experiments. 47, 48 The reverse situation, however, might also occur in these patients, as phosphoantigen-activated cd T cells can overcome Tregs 49 and TGF-b immunosuppressive functions. 50 The above trials demonstrated that Tregs were not significantly induced by these regimens involving only low doses of IL-2, and they did not offer evidence of Treg-based cd T-cell immunosuppression. Therefore, although the utilization of IL-2 in these trials was a concern, its use did not hamper clinical responses. However, this issue highlights the need for investigating new methods that will activating cd T cells using IL-2-free protocols.
Lessons from cd T cell-based cancer immunotherapy trials JJ Fournié et al 38 LESSON II: REMAINING ISSUES Autologous cd T lymphocyte-based cell therapy is now feasible and safe but technically more demanding than PAG/IL-2 injection in patients. The advantage of this type of therapy is the ability to produce highly controlled amplification ex vivo, opening the possibility of further modifying the growing cells throughout the culture process, by supplementation of the cytokine supply, for example. Furthermore, this method theoretically opens the possibility of expanding the cells more efficiently ex vivo for hyporesponsive patients in which PAG/IL2 would otherwise fail to induce a strong response. The manufacturing process has specific Good Manufacture Practice constraints to respect, but protocols for large-scale expansions (.1000-fold) of TCRVc9Vd2 1 cd T cells are now available, albeit costly. Using welldefined protocols, it is now possible to produce batches of several billion (2310 9 to 10 10 ) cd cells from blood samples within 2 weeks. For autologous transplantation, however, the produced batches of cells must meet certain requirements for cell purity, including frequency of TCR cd cells (.70% appears to be a reasonable threshold). 39, 51 These thresholds might lessen the number of batches available to reinject into patients, as the batches might not meet the requirements either in cell number or cell purity. Although these are obvious technical limitations, such autologous cd cell infusions are safe and well tolerated, as they induce an identical spectrum of symptoms as those induced by phosphoantigens alone (as mentioned above), but not those of zoledronate. Despite these limitations, autologous cd T lymphocyte-based cell therapy demonstrates signs of clinical efficacy, demonstrating the therapeutic potential of this method in cancer immunotherapy.
Activation-induced cd T-cell anergy has repeatedly been reported in most, if not all, in vivo studies in patients. Similar observations had been made in nonhuman primates, through either activation with BrHPP/IL2 alone 15, 46 or in antituberculous vaccine trials. 52 The underlying molecular basis of this process still remains unknown but could conceivably be attributed to inadequate activation conditions. This condition could possibly result from absent signals delivered to the cd cells during the activation process, from suboptimal exposure to phosphoantigens or from TCRVc9Vd2 1 cd T cellintrinsic physiological characteristics not found in ab T cells. Our lack of knowledge on this issue represents an obvious limitation to the broader use of cd cells in cancer therapy. Indeed, most currently available trials demonstrate evidence of some clinical benefits in patients, but these benefits most likely result from 'one shot' in vivo responses by cd T cells.
Immunoescape by cancer cells remains an important issue for cd cell-based strategies. Indeed, a growing body of evidence demonstrates that cancer cells develop an ability to avoid checkpoints introduced by the immune system and that tumors differ in regard to the pathways used to avoid their own immune-mediated destruction.
It has been suggested that tumor progression could be thwarted by cd cell-induced responses. This concept was recently validated by a clinical study on the treatment of 21 adult patients with advanced renal cell carcinoma, malignant melanoma and acute myeloid leukemia with zoledronate/IL-2 (low-dose). This phase I/II trial underwent a total of 58 treatment cycles to assess the safety, pharmacodynamics and antitumor activity of the treatment. In addition to reporting standard levels of safety, the authors reported significant cd cell activation (quantitated by IFN-c production) and expansion in all evaluable patients but no objective responses in either of the cohorts with solid tumors. By contrast, two patients with acute myeloid leukemia achieved objective tumor responses, namely partial remission. Most interestingly, Kunzmann and colleagues noticed an unexpected increase in serum VEGF in response to zoledronate/IL-2 and found that this spike correlated with a lack of clinical response. 53 Therefore, the authors concluded that cd cell-derived VEGF induced by the treatment can limit clinical outcomes by harnessing innate tumor immunity. Transcriptome profiling of TCRVc9Vd2 1 cd T lymphocytes revealed that these cells upregulate expression of VEGF upon activation, 54 raising a special consideration for angiogenesisdependent solid tumors.
Immunoevasion strategies that specifically protect against cd cell functions can involve diverse cellular and molecular mediators (reviewed in Refs. 55 and 56) which have the potential to have impacted the outcome of the above trials. For example, tumor-derived PGE2 is a potent cd T-cell immunosuppressive mediator, 57, 58 but this variable was neither considered nor monitored in the aforementioned assays. The potent immunosuppressor TGF-b, which is frequently secreted by human cancers, is capable of repressing cytotoxic immune responses, although the bioactivity of this molecule can be counterbalanced by augmenting its activation with phosphoantigens. 50 There are currently few case reports, however, depicting a tumor cell relapse following a therapeutic response to cd T cell-based immunotherapy. Nevertheless, the aforementioned trials only involved patients with advanced and relapsing metastatic renal cancers, prostate cancer and B-cell lymphomas. Such evolved tumor cells carry massive genetic alterations and are therefore able to suppress all steps of immune action, namely, the recruitment of, engagement by and function of cytolytic cells. [59] [60] [61] [62] Additional tumor-extrinsic criteria, such as the genotype of the patient, can also impact the clinical outcome. Efficacy of the treatment in the relapsing follicular lymphoma patients was expected to result from the enhancement of ADCC by rituximab/ BrHPP/IL-2 co-administration. Indeed, polymorphisms in the IgG Fc receptor FccRIIIa gene strongly affect the efficacy of ADCC in patients undergoing rituximab-based therapies 63 and the individual pharmacokinetics for each patient. 64 Therefore, genotyping patients and determining their cancer biomarkers prior to the use of cd cell-based protocols could provide patients with the most appropriate options. A primary effort in this direction is the integration of cd cell-based therapies and drugs for which ADCC-based therapeutic activity is independent of FccRIIIa polymorphisms, such as the more recent anti-CD20 antibodies.
THE FUTURE OF cd T-CELL CANCER IMMUNOTHERAPIES
To be successful, cancer immunotherapies involving cd cells will require updated protocols that limit anergy and the use of drugs able to overcome immunoescape. Although the former contingency is currently an open issue, the second is already well underway. Indeed, ongoing therapies against cancer immunoescape include nonspecific immune stimulation by IL-2, IFN-a, cyclophosphamide, TLR agonists (e.g., imiquimod and resiquimod), the BCG vaccine and biomolecules such as the anti-CD25 mAb or the IL-2-diphtheria toxin conjugate. By inducing immunogenic cell death during chemotherapy, anthracyclins might also present this bioactivity. 65 Ongoing and recently completed clinical trials against cancer immunoescape also involve monoclonal antibodies blocking PD1, PDL1 and CTLA4, while several other cancer vaccines and cell transfer strategies are also underway. In addition, several new therapeutic monoclonal antibodies against tumor cell antigens are now rapidly progressing through phase I-III trials, and some therapeutic successes will undoubtedly emerge with these new drugs. Therefore, novel regimens that combine such drugs with cd cell-based strategies, either with phosphoantigens or with cd T Lessons from cd T cell-based cancer immunotherapy trials JJ Fournié et al 39 cells, are currently being considered and investigated by translational research labs around the world. These avenues will undoubtedly represent the next frontier for immunotherapeutic innovations in cancer research.
